Floatz logo

OTENABANT

Hepatic Insufficiency

PfizerSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Hepatic Insufficiency cohort.

Asset / SponsorPhaseRating
Empagliflozin
Yale University
Phase 4BB
Avatrombopag
Tongji Hospital
Phase 4BB
Pentoxifylline
Assistance Publique - Hôpitaux de Paris
Phase 3BB
Erythropoietin Human Recombinant
Institute of Liver and Biliary Sciences, India
Phase 3BB
Everolimus
Azienda Ospedaliera di Padova
Phase 2B

View all 24 →

Same molecule, other indications

OTENABANT is also rated in:

obesity disorderDormant
B
Indicative ·
57 / 100
View asset →
Pain, NerveDormant
B
Indicative ·
57 / 100
View asset →
Non-Alcoholic Steatohepatitis(NASH)Dormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →